Financial Statement Details (Tables)

12 Months Ended

Dec. 31, 2020

As of December 31, 2020 and 2019, prepaid expenses and other current assets consist of the following (in thousands):


	As of December 31,
	2020		2019
Prepaid preclinical and clinical trial services - with related party (Note 9)	$	4,626	$	1,021
Insurance claim receivable		2,518		6,384
Insurance premium financing asset		1,421		757
Prepaid manufacturing services		—		1,919
Prepaid insurance		1,365		793
Prepaid services		1,294		570
Prepaid license fees		801		614
Interest receivable - marketable debt securities		473		222
Grant receivable		—		402
Prepaid equipment maintenance		243		251
Prepaid supplies - with related party (Note 9)		143		—
Laboratory equipment deposit		66		—
Prepaid rent		52		392
Other		647		677

Prepaid expenses and other current assets	$	13,649	$	14,002

As of December 31, 2020 and 2019, property, plant and equipment, net, consist of the following (in thousands):


	As of December 31,
	2020			2019
Leasehold improvements	$	52,251		$	51,314
Equipment		34,738			32,885
Buildings		22,690			22,872
Software		2,376			2,282
Furniture & fixtures		1,015			948
Construction in progress		1,333			1,333

Subtotal		114,403			111,634
Less: accumulated depreciation		(41,862	)		(28,165	)

Property and equipment, net	$	72,541		$	83,469

As of December 31, 2020 and 2019, other assets consist of the following (in thousands):


	As of December 31,
	2020		2019
VAT receivable	$	864	$	697
Security deposits		634		240
Prepaid software license fees		455		—
Restricted cash		179		179
Prepaid preclinical and clinical trial services - with related party (Note 9)		92		4,075
Due from related party		51		19
Others		323		308

Other assets	$	2,598	$	5,518

As of December 31, 2020 and 2019, accrued expenses and other liabilities consist of the following (in thousands):


	As of December 31,
	2020		2019
Accrued professional and service fees	$	7,668	$	3,943
Accrued dissenting shares (Note 8)		6,769		6,335
Accrued bonus		5,288		4,121
Accrued preclinical and clinical trial costs		4,339		2,444
Accrued research and development costs		4,002		392
Accrued compensation		3,891		2,777
Financing obligation - current portion		1,421		757
Accrued contingent consideration payable		856		786
Accrued laboratory equipment and supplies		641		640
Accrued capital expenditures		337		—
Deferred revenue		270		162
Accrued franchise, sales, use and property taxes		103		200
Accrued other		1,186		928

Accrued expenses and other liabilities	$	36,771	$	23,485

Net investment income included the following for the years ended December 31, 2020 and 2019 (in thousands):


	For the Year Ended December 31,
	2020			2019
Interest income	$	1,725		$	2,764
Unrealized gain (loss) from equity securities	$	1,577		$	(321	)
Investment (amortization expense) accretion income, net		(858	)		3
Net realized (losses) on investments		(9	)		(4	)

	$	2,435		$	2,442